Off-Patent Antioxidant Compound Restores Neural Connectivity in Multiple Sclerosis Patients

Current disease-modifying therapies for multiple sclerosis operate under a strict biological constraint: they dampen an overactive immune system to prevent new lesions, but they cannot repair the damage already done. For the 2.8 million people living with the disease worldwide, that leaves the underlying neurodegeneration largely unchecked.[1]

A significant driver of that ongoing damage is oxidative stress, a cellular imbalance that most approved medications simply do not target. Researchers have long sought a way to intervene in this pathway to halt or reverse the cognitive and physical decline that patients experience over time.

Now, a small clinical trial has demonstrated that an inexpensive, off-patent compound might bridge that therapeutic gap. By adding a widely available antioxidant to standard care, researchers observed restored functional connectivity in the brains of patients with multiple sclerosis.[1][2]

The findings, published in late 2026 in IBRO Neuroscience Reports, offer an early but compelling imaging signal that neural networks disrupted by the disease can be coaxed back into communication. The approach targets the brain's metabolic health rather than just its immune environment.[2]

Repurposing a common antioxidant

The compound at the center of the trial is N-acetylcysteine, commonly known as NAC. It is an off-patent drug with a long history of safe use in emergency medicine, where it is administered intravenously to prevent liver failure in cases of acetaminophen overdose.[1]

NAC works by directly targeting oxidative stress, raising the body's levels of glutathione. Glutathione is a naturally occurring antioxidant that protects cells from damage, but people living with multiple sclerosis typically show depleted levels of these protective molecules in their brains.[1]

"Every hospital has it," said Dr. Daniel Monti, professor and chair of the Department of Integrative Medicine and Nutritional Sciences at Thomas Jefferson University, who led the research. "It's used in Tylenol overdose cases, in which oxidative stress is one of the contributors to liver failure."[1]

Because the drug is already widely manufactured and its safety profile is well understood, it bypasses many of the developmental hurdles that slow new therapies. The research team hypothesized that restoring the brain's antioxidant capacity could help neurons recover their metabolic function.

"You could say we're replenishing rather than supplementing," Monti explained, noting that the treatment aims to restore a biological baseline that the disease has eroded. In previous pilot studies, patients receiving the compound had reported experiencing less fatigue and lower anxiety.[1]

Tracking brain connectivity

To rigorously test the compound's effects on brain function, the research team enrolled patients with mild to moderate multiple sclerosis in 2026. The participants were randomized into two groups: one receiving standard care alone, and another receiving standard care plus a specific regimen of NAC.[2]

The treatment group received a robust, dual-route dosage over a four-month period. Patients were given 50 milligrams per kilogram of intravenous NAC once a week, supplemented by 500 milligrams of oral NAC taken twice daily on the remaining six days of the week.

Researchers evaluated the participants at the beginning of the trial and again after four months using an integrated PET-MRI platform. This dual-imaging approach allowed the team to simultaneously measure blood oxygen level-dependent functional connectivity and cerebral glucose metabolism.[2]

The results showed significant connectivity alterations in the brains of patients who received the antioxidant. The functional MRI scans revealed enhanced communication in the inferior frontal region, the cerebellum, and parts of the temporal and parietal lobes compared to the control group.[2]

"It's a measure of how different parts of the brain are working together," said Dr. Andrew Newberg, director of the university's PET/MRI imaging program and a co-author of the study. The imaging provided concrete visual evidence of the drug's impact on neural networks.[1]

Metabolic recovery and clinical outcomes

The structural improvements seen on the MRI were matched by metabolic gains visible on the PET scans. Fluorodeoxyglucose PET imaging revealed that the treatment group experienced corresponding increases in cerebral glucose metabolism in several of the same brain areas.[2]

Increased glucose metabolism indicates that neurons in those regions are firing more actively and efficiently. For patients whose neural pathways have been compromised by demyelination and oxidative stress, this metabolic boost represents a partial restoration of normal brain function.

"Multiple sclerosis is breaking connections and NAC helps reestablish them," Newberg said, summarizing the dual imaging findings for the research team. "In short, it helps the brain work better." The scans provided the first simultaneous evidence of these dual benefits.[1]

These physiological changes translated into tangible benefits for the patients. Those in the treatment group reported statistically significant improvements in their clinical symptom questionnaires after four months, while the control group did not experience similar gains.

Specifically, the participants receiving the antioxidant recorded better scores on measures of pain, fatigue, cognition, and attention. The self-reported improvements in cognitive focus directly correlated with the areas of the brain that showed increased metabolic activity on the scans.

AI

Early signals require confirmation

Despite the promising results, clinical pharmacology experts caution against overinterpreting the data. The Healthcare Communications Network noted that the findings represent an early imaging signal rather than established evidence of long-term disease modification or reduced disability progression.[3]

The trial's small sample size and short four-month duration limit the ability to draw definitive conclusions about the drug's ultimate efficacy. The study was designed to be hypothesis-generating, proving that the mechanism works in humans before launching a massive, multi-center trial.[3]

Medical analysts also stress that the imaging changes do not independently guarantee lasting improvements in patient-centered outcomes. While the early cognitive and fatigue benefits are encouraging, they must be replicated in larger cohorts to ensure they are durable and broadly applicable.[3]

Furthermore, the researchers emphasize that the antioxidant was studied strictly as an adjunctive treatment. It is designed to complement, not replace, existing disease-modifying therapies that remain essential for controlling the autoimmune inflammation at the root of the disorder.[1][3]

Experts also warn patients against attempting to replicate the trial's results using over-the-counter supplements. The study utilized a specific, high-dose combination of intravenous and oral administration that cannot be matched by simply purchasing oral capsules at a pharmacy.[3]

Expanding the therapeutic window

The success of the trial opens new avenues for treating the neurodegenerative aspects of multiple sclerosis. Because the compound is safe and off-patent, it represents a low-risk addition to the therapeutic arsenal that could be rapidly deployed if larger trials confirm the benefits.[1]

"There's so little downside, because it's such a safe compound," Monti noted. The research team is now planning larger-scale studies to verify the initial findings, establish the most effective dosing regimens, and track the long-term clinical outcomes for patients.[1]

AI

The implications of the research extend beyond multiple sclerosis. The underlying mechanism of oxidative stress contributes to cellular damage in a wide range of neurological conditions, suggesting the antioxidant approach could have broader applications in neurology.[1]

Newberg pointed out that the team has already observed similar changes in dopamine function and functional connectivity when administering the compound to patients with Parkinson's disease. The drug's ability to cross into the brain and raise glutathione levels makes it a versatile tool.[1]

Monti is also encouraged to test the compound in patients recovering from traumatic brain injuries, where oxidative stress plays a major role in the secondary damage following an impact. "So far, NAC has been a winner," he said.[1]